Reishi & STAT3 Signalling in Cancer: ER+ Breast Cancer Research Findings

Ganoderma lucidum (Reishi) is one of the most studied medicinal mushrooms in oncology, with accumulating preclinical evidence that its bioactive compounds — predominantly triterpenes (ganoderic acids) and polysaccharides (beta-glucans) — interfere with multiple oncogenic signalling cascades. The STAT3 (Signal Transducer and Activator of Transcription 3) pathway sits at the intersection of immune evasion, tumour stemness, therapy resistance, and cancer cell survival. Reishi's capacity to suppress STAT3 is therefore highly relevant for cancer support groups — and particularly for those navigating ER+ breast cancer, where STAT3 activation is now understood to be a key driver of endocrine resistance and disease progression.

This report synthesises the current preclinical and clinical research landscape, separating findings by breast cancer subtype where evidence exists, and situating ER+ disease within the broader STAT3/JAK2 biology.

Understanding STAT3 in Breast Cancer

STAT3 is a transcription factor activated by a cascade typically triggered by cytokines (especially IL-6), growth factors (EGF, VEGF), and receptor tyrosine kinases. The canonical activation route runs: ligand → receptor → JAK2 phosphorylation → STAT3 phosphorylation at Tyr705 → STAT3 dimerisation → nuclear translocation → target gene transcription.[1][2]

Once constitutively active, STAT3 drives a range of pro-tumour effects:

• Upregulation of anti-apoptotic proteins (Bcl-2, Survivin, Mcl-1)

• Promotion of cell cycle progression (Cyclin D1)

• Stimulation of angiogenesis (VEGF)

• Maintenance of cancer stem cell (CSC) self-renewal and the stem marker phenotype (ALDH1+, CD44+/CD24−)[3][4]

• Suppression of immune cell activity in the tumour microenvironment

Aberrant STAT3 phosphorylation is reported in up to 70% of solid and haematologic cancers, and in breast cancer specifically, constitutive STAT3 activation has been observed across all major subtypes, though its role is most mechanistically established in TNBC and its relationship to endocrine resistance in ER+ disease is now a rapidly evolving area.[^5]

STAT3 and ER+ Disease: The Endocrine Resistance Connection

For ER+ breast cancer patients on tamoxifen or aromatase inhibitors, STAT3 is emerging as a critical resistance mechanism. Key findings:

• EGFR–Src–STAT3 axis in tamoxifen resistance: Studies using ER+ cell lines (MCF-7 and T47D) established that prolonged tamoxifen exposure progressively elevates phospho-STAT3 (p-STAT3) expression. Tamoxifen-resistant cells (TamR) show significantly increased levels of phosphorylated Src, EGFR (Y845), and STAT3 compared to parental cells. Direct STAT3 inhibition with stattic strongly restored tamoxifen sensitivity in TamR cells, and knockdown of STAT3 via siRNA specifically enhanced tamoxifen efficacy in resistant (not naïve) cells.[6][7]

• IL-6/STAT3 cascade and endocrine failure: A separate mechanistic study demonstrated that IL-6 and IL-6R upregulation — driven by a splice variant of NCOR2 — activates STAT3 and constitutes an independent pathway to tamoxifen resistance in ER+ primary breast cancer. IL-6R expression in clinical samples was significantly associated with tamoxifen resistance and correlated with poorer overall and disease-specific survival.[^8]

• These findings establish a clear rationale for STAT3 inhibition as a strategy to both prevent and reverse endocrine resistance in ER+ disease — making Reishi's STAT3-targeting properties directly relevant to this patient population.

How Reishi Suppresses STAT3: Key Mechanisms

Ganoderic Acid A — Direct JAK2/STAT3 Inhibition

The most characterised STAT3-targeting compound in Reishi is ganoderic acid A (GA-A), a lanostane-type triterpene. Research published in Oncology Letters (2018) demonstrated that GA-A exerts antitumour activity against MDA-MB-231 breast cancer cells by directly inhibiting JAK2 phosphorylation and the downstream activation of STAT3. Specifically, GA-A:[9][1]

• Suppresses STAT3 target gene expression

• Leads to increased levels of proteins associated with mitochondrial apoptosis

• Inhibits breast cancer cell viability in a dose-dependent manner

A comprehensive 2024 review in Frontiers in Oncology confirmed GA-A's classification as a JAK2-targeting compound in preclinical breast cancer studies, placing it alongside pharmaceuticals in a systematic table of JAK2 inhibitors tested against TNBC. The mechanism (JAK2 blockade → reduced STAT3-Tyr705 phosphorylation) mirrors that of dedicated JAK inhibitors like Ruxolitinib, but GA-A appears to act without the systemic haematological toxicities associated with pharmaceutical JAK2 inhibitors.[^2]

Additionally, ganoderic acid A has been shown to modulate the JAK3/STAT3 and NF-κB pathways in inflammatory models, and a 2025 review catalogued its JAK/STAT pathway inhibition as one of multiple anti-cancer mechanisms operating in breast cancer cell lines.[10][1]

GLE (Whole Extract) — STAT3 and Cancer Stem Cell Pathway Suppression

Beyond isolated ganoderic acid, whole Ganoderma lucidum extract (GLE) — which contains polysaccharides (~13.5%), triterpenes (~6%), and cracked spores (~1%) — has been studied as a STAT3-targeting agent in the context of breast cancer stem cells (BCSCs).

The landmark 2018 study in Oncotarget (Rios-Fuller et al.) provided the first molecular mechanistic evidence that GLE targets BCSCs specifically through the STAT3 pathway:[4][3]

• GLE significantly reduces TNBC cell viability in a dose-dependent manner

• GLE down-regulates both total and phosphorylated STAT3 (Tyr705) in breast cancer cells

• GLE reduces expression of stemness transcription factors OCT4, NANOG, and SOX2 — all downstream of STAT3

• GLE depletes the ALDH1+ and CD44+/CD24− BCSC population — the same markers used clinically to identify therapy-resistant stem-like cells

• GLE disrupts mammosphere (tumour sphere) formation

• In in vivo xenograft models, GLE significantly reduced tumour volume and weight (~50% reduction over 13 weeks) from sorted CD44+/CD24− BCSCs, with no systemic toxicity[3][4]

The mechanistic pathway in these cells: GLE → reduced IL-6 secretion (in MDA-MB-231 cells) → reduced JAK2 activation → reduced STAT3-Tyr705 phosphorylation → reduced OCT4/NANOG/SOX2 → BCSC depletion.[^3]

Reishi and ER+ Breast Cancer: Direct Evidence

ERα Downregulation in MCF-7 Cells

The most direct evidence for Reishi's relevance in ER+ breast cancer comes from studies using MCF-7 cells — the standard in vitro model for ER+ (luminal A) breast cancer. A key study (Sliva et al., published in the International Journal of Oncology) demonstrated that G. lucidum inhibited the proliferation of ER+ MCF-7 cells through dual inhibition of the estrogen receptor and NF-κB signalling:[11][12]

• G. lucidum down-regulated ERα expression in MCF-7 cells — without affecting ERβ expression

• G. lucidum inhibited both estrogen-dependent and constitutive transactivation of ER through the estrogen response element (ERE)

• G. lucidum decreased TNF-α-induced NF-κB activity in MCF-7 cells

• The combined suppression of ER and NF-κB resulted in down-regulation of c-myc expression and suppression of proliferation in both ER+ (MCF-7) and ER− (MDA-MB-231) cells

• Cell cycle arrest was induced at G0/G1 phase, mediated by suppression of the Akt/NF-κB pathway[12][11]

This is significant: by downregulating ERα, Reishi acts on the very receptor that drives ER+ breast cancer growth, while simultaneously suppressing the NF-κB pathway that cross-talks with STAT3 to maintain tumour survival.

PI3K/AKT/mTOR Pathway Suppression — Relevant to ER+ Resistance

Research in inflammatory breast cancer (IBC) cells — while not ER+ — demonstrated that Reishi downregulates the PI3K/AKT/mTOR and MAPK/ERK pathways, reducing protein synthesis and tumour growth by approximately 50% in xenograft models. These pathways are also central to endocrine resistance in ER+ disease, where PI3K pathway mutations (particularly PIK3CA) drive resistance to aromatase inhibitors and CDK4/6 inhibitors.[13][14]

Furthermore, a 2024 study identified ganoderic acid DM (GADM) as an inhibitor of PIK3CA protein expression in breast cancer cell lines — the very gene most commonly mutated in ER+ breast cancer. GADM suppressed PIK3CA in a dose-dependent manner, with researchers noting its potential as a combination therapy agent to overcome drug resistance.[15][16]

Signalling Pathways: Summary of Reishi's Targets

Cancer Stem Cells: A Key Intersection

The relationship between STAT3 and cancer stem cell (CSC) biology is particularly relevant for cancer patients focused on reducing recurrence. STAT3 is a master regulator of the CSC phenotype — it maintains stemness by controlling expression of OCT4, SOX2, and NANOG, and is constitutively active in CD44+/CD24− and ALDH1+ cells. These CSC populations are the primary source of therapy resistance, metastasis, and relapse across all breast cancer subtypes.[17][3]

Reishi extract's ability to:

1. Deplete ALDH1+ cells (nearly 3-fold reduction in one study)[^3]

2. Reduce CD44+/CD24− stem populations (from 94% to 42.5% in MDA-MB-231 cells)[^3]

3. Disrupt mammosphere formation[4][3]

4. Downregulate OCT4, NANOG, and SOX2[^3]

5. Reduce STAT3-Tyr705 phosphorylation in tumour tissue in vivo[^3]

...all point to an anti-stemness mechanism that complements — and may enhance — conventional therapies. For ER+ patients, this is especially relevant given the role of CSCs in late recurrence (which is more common in luminal breast cancers than in TNBC).

Clinical and Human Data

Preclinical findings are compelling, but human evidence remains limited and primarily in immune/quality-of-life outcomes. Key clinical observations:

• Immune enhancement: In patients with advanced-stage cancer (n=34), a reishi polysaccharide preparation (1,800 mg, 3× daily, 12 weeks) elevated IL-2, IL-6, and interferon-gamma, and increased NK cell activity[^18]

• Improved chemotherapy response: A meta-analysis found patients treated with reishi as an adjunct to chemotherapy or radiation were 1.27 times more likely to respond to treatment than controls[^19]

• Breast cancer fatigue/aromatase inhibitors: A Phase II clinical trial (NCI-2023-06578) is currently investigating Reishi mushroom extract specifically for fatigue and arthralgias/myalgias in breast cancer patients on aromatase inhibitors — the standard endocrine therapy for ER+ breast cancer[^20]

• Quality of life: A study in breast cancer patients receiving hormone therapy found that Reishi spore powder may improve fatigue and mental health[^19]

• Pilot breast cancer study: A pilot study found that spore powder of G. lucidum may have beneficial effects on cancer-related fatigue and quality of life in breast cancer patients[^21]

Important Safety and Interaction Considerations

Reishi has a generally favourable safety profile, but the following are relevant for cancer patients:

Evidence Gaps and Research Limitations

The research landscape has several important limitations that advocacy group members should understand:

1. Most STAT3/Reishi studies are in TNBC cells, not ER+ cells: The JAK2/STAT3 pathway is hyperactivated in TNBC; the ER+ MCF-7 data primarily shows ERα and NF-κB effects, not direct STAT3 targeting[11][12]

2. No human trials have directly measured STAT3 suppression by Reishi: All STAT3 data is preclinical (cell culture and mouse models)

3. Variability in Reishi preparations: Commercial extracts differ widely in polysaccharide and triterpene ratios, making dose comparisons across studies challenging[^3]

4. IL-6 complexity: While Reishi suppresses IL-6 secretion in some cancer cell lines, IL-6 elevated by reishi polysaccharides in clinical studies may have different immune-modulating roles in healthy vs. tumour-bearing tissues[18][3]

5. ER+/HER2+ interaction: How Reishi interacts with HER2-targeted therapies or CDK4/6 inhibitors in ER+/HER2+ or ER+/CDK4/6-inhibitor settings has not been studied

Conclusion

The current evidence supports Reishi (Ganoderma lucidum) as a biologically plausible adjunctive agent in ER+ breast cancer, with mechanistic relevance across several key pathways:

• Direct STAT3 pathway suppression via ganoderic acid A (JAK2 → STAT3-Tyr705 axis)[1][9]

• ERα downregulation in ER+ MCF-7 cells — directly targeting the oestrogen-driven growth mechanism[12][11]

• NF-κB suppression that cross-talks with STAT3 to maintain tumour survival

• PIK3CA inhibition (ganoderic acid DM) — relevant to the most common resistance mutation in ER+ disease[^16]

• Cancer stem cell depletion through the STAT3/OCT4/NANOG/SOX2 axis — addressing the biological roots of late recurrence[4][3]

• Potential reversal of endocrine resistance through STAT3 inhibition, based on the mechanistic data in ER+ tamoxifen-resistant cell lines[7][6][^8]

The pivotal gap remains the absence of human trials directly testing these molecular effects in ER+ patients. The ongoing NCI Phase II trial in aromatase inhibitor-using patients represents an important step, though its primary endpoints are symptom-focused rather than tumour-biological. Advocacy group members and their oncology teams should be aware that while the mechanistic case is building, clinical confirmation of STAT3 suppression and anti-tumour effects in ER+ humans remains the critical unmet need in this research space.[^20]

References

1. Research progress on the signaling pathway mechanism of ... - PMC - The triterpenoid ganoderic acid A can directly inhibit JAK2 phosphorylation and downstream activatio...

2. Potential therapeutic targets of the JAK2/STAT3 signaling pathway ... - Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer ... acid suppresse...

3. Ganoderma lucidum extract (GLE) impairs breast cancer stem cells ... - Analysis of the BCSC compartment in tumors revealed that GLE decreases the STAT3 pathway and the exp...

4. Ganoderma lucidum extract GLE impairs breast cancer stem cells by ... - Analysis of the BCSC compartment in tumors revealed that GLE decreases the STAT3 pathway and the exp...

5. [PDF] Leveraging STAT3 Signaling for Advanced Cancer Therapeutics - STAT3 phosphorylation is reported in up to 70% of solid and hematologic cancers including multiple m...

6. Inhibition of STAT3 enhances sensitivity to tamoxifen in ... - PubMed - ... STAT3 can cause tamoxifen resistance in ER-positive breast cancer cells. Both dasatinib (Src inh...

7. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen ... - ... STAT3 can cause tamoxifen resistance in ER-positive breast cancer cells. Both dasatinib (Src inh...

8. Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen ... - We previously identified BQ323636.1 (BQ), a novel splice variant of NCOR2, can robustly predict tamo...

9. Ganoderic acid A exerts antitumor activity against MDA-MB-231 ... - In conclusion, GA-A treatment inhibited breast cancer cell viability via JAK2/STAT3 downregulation a...

10. Ganoderic Acids A + B: Unlocking the Medicinal Power of Reishi - These triterpenes inhibit key inflammatory markers like TNF-α and IL-6. This effect makes them poten...

11. Ganoderma lucidum inhibits proliferation of human breast cancer ... - We show that G. lucidum inhibited the proliferation of breast cancer MCF-7 and MDA-MB-231 cells by t...

12. Ganoderma lucidum inhibits proliferation of human breast cancer ... - Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen...

13. Anti-Tumor Effects of Ganoderma lucidum (Reishi) in Inflammatory ... - Our results provide evidence that Reishi suppresses protein synthesis and tumor growth by affecting ...

14. Anti-Tumor Effects of Ganoderma lucidum (Reishi) in Inflammatory ... - Our results provide evidence that Reishi suppresses protein synthesis and tumor growth by affecting ...

15. New Study Identifies Ganoderic Acid DM as Potential Treatment for ... - These findings suggest that GADM could be a reliable potential treatment for breast cancer by inhibi...

16. New study identifies ganoderic acid DM as potential treatment for ... - These findings suggest that GADM could be a reliable potential treatment for breast cancer by inhibi...

17. STAT3 and p63 in the Regulation of Cancer Stemness - Frontiers - STAT3 is a regulative factor for normal and cancer stem cells (CSCs). Tumor protein p63 (p63), a mem...

18. Reishi Mushroom - The ASCO Post - Current data from small studies suggest that reishi improves immune response in patients with cancer...

19. Can Reishi Mushrooms Help With Breast Cancer? - A few small studies show certain reishi preparations may enhance immunity and reduce side effects fr...

20. Reishi Mushroom Extract for Fatigue and/or Arthralgias/myalgias in ... - Reishi mushroom extract works in treating fatigue and/or joint/muscle pain (arthralgias/myalgias) in...

21. Reishi Mushroom Extract for Breast Cancer-Related Fatigue and ... - This pilot study suggests that spore powder of Ganoderma lucidum may have beneficial effects on canc...

22. Reishi Mushroom | Memorial Sloan Kettering Cancer Center - In small clinical studies, reishi increased plasma antioxidant capacity, enhanced both immune and tu...